Development Pipelines

Hematologic Oncology Pipeline

PharmaEssentia’s hematologic oncology pipeline comprises candidates across a range of indications in development. Through innovative science, we intend to expand into other areas where our technology can address the unmet medical needs in myeloproliferative neoplasms.

Hematology

Candidate
Indication
Market
Preclinical
Phase I/II
Phase III
Regulatory
Approval
Ropeginterferon alfa-2b
(P1101)
PV
See clinical trial
US
EU, TW, KR, JP, CH, IL, SG, CN, AR, BR
MY, HK
ET
See clinical trial
Global
Early Myelofibrosis
Global
Adult T-Cell Leukemia
JP, TW, CN
CML
KR
Early Myelofibrosis
Adult T-Cell Leukemia
CML
Global
Global
JP, TW, CN
KR

PV, polycythemia vera; ET, essential thrombocythemia; CML, chronic myeloid leukemia

AR, Argentina; BR, Brazil; CH, Switzerland; CN, China; EU, European Union; IL, Israel; JP, Japan; KR, Korea; MY, Malaysia; SG, Singapore; TW, Taiwan; US, United States

PharmaEssentia USA Corporation
35 Corporate Drive, Suite 325,
Burlington, MA 01803, USA

This website may include information on investigational products or uses that have not been approved by the U.S. FDA. PharmaEssentia does not support, endorse, or recommend the unapproved use of any compound. This site includes information on clinical trials for approved and investigational compounds and indications. This information is not intended to be medical advice. By using this website, you confirm the unsolicited nature of your request.

© 2026 PharmaEssentia Corporation. All rights reserved.
PharmaEssentia and the PharmaEssentia logo are trademarks or registered trademarks of PharmaEssentia Corporation.

Web Design and Development by RainCastle Communications.